Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Stephen Fa
Nov 21, 2023 8:30AM ET
MDT is still a good buy.
0
0
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
Final hours: unlock premium data with Claim 60% OFF
Medtronic shrugs off concerns over newer weight-loss drugs, raises annual forecast
Published Nov 21, 2023 06:52AM ET
Updated Nov 21, 2023 11:25AM ET
© Reuters. FILE PHOTO: Medtronic Plc logo is seen displayed in this illustration taken, April 10, 2023. REUTERS/Dado Ruvic/Illustration/File Photo
By Khushi Mandowara and Christy Santhosh
(Reuters) -Medtronic raised its annual earnings forecast on Tuesday as strong sales in its surgical and diabetes units allayed concerns about the impact of new diabetes and weight-loss drugs on long-term growth, sending its shares up nearly 4% in morning trade.
Makers of medical products used in bariatric surgery and glucose-monitoring devices have been trying to ease investor concerns over a potential hit to demand from the rising popularity of new GLP-1 drugs like Novo Nordisk (NYSE:NVO)'s Ozempic and Eli Lilly (NYSE:LLY)'s Mounjaro.
Medtronic (NYSE:MDT)'s CEO Geoffrey Martha said GLP-1 drugs would have a modest but temporary impact on the bariatric surgery market.
Dublin-based Medtronic joins peers Johnson and Johnson and Abbott Laboratories (NYSE:ABT) in playing down the impact of GLP-1 drugs, which suppress hunger in patients.
"Bariatric surgery will continue to remain the gold standard for addressing obesity," Martha said, adding that many patients who try these drugs will not stay on them for more than a year due to concerns related to costs and side effects.
Over the long term, health care costs may be delayed with the use of GLP-1s but not eliminated, limiting the impact on medical-device companies, said John Boylan, analyst at Edward Jones.
When asked about a possible spin-off or sale of its respiratory and patient-monitoring units, Martha confirmed to Reuters that Medtronic is continuing to work on the separation, which is expected by the first half of the next fiscal year.
Sales in Medtronic's diabetes unit stood at $610 million, beating estimates of $588.4 million. Martha expects diabetes devices to drive the company's sales growth in the second half of the fiscal year.
It now estimates profit per share between $5.13 and $5.19 for the fiscal year ending in April 2024, above the previous $5.08 to $5.16 per share range.
Medtronic beat adjusted profit by 7 cents for the quarter ended Oct. 27, according to LSEG data.
Related Articles
Comments (1)
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.